IPI-549
- Generic Name
- IPI-549
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C30H24N8O2
- CAS Number
- 1693758-51-8
- Unique Ingredient Identifier
- FOF5155FMZ
- Background
IPI-549 is under investigation in clinical trial NCT03795610 (Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma).
- Associated Conditions
- -
- Associated Therapies
- -
Window of Opportunity Study of IPI-549 in Patients With Locally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma
- First Posted Date
- 2019-01-08
- Last Posted Date
- 2023-03-10
- Lead Sponsor
- Ezra Cohen
- Target Recruit Count
- 15
- Registration Number
- NCT03795610
- Locations
- 🇺🇸
UC San Diego Moores Cancer Center, La Jolla, California, United States
A Study to Evaluate Safety/Tolerability of Immunotherapy Combinations in Participants With Triple-Negative Breast Cancer or Gynecologic Malignancies
- First Posted Date
- 2018-10-25
- Last Posted Date
- 2024-05-24
- Lead Sponsor
- Arcus Biosciences, Inc.
- Target Recruit Count
- 35
- Registration Number
- NCT03719326
- Locations
- 🇦🇺
Peninsula & South Eastern Haematology and Oncology Group, Frankston, Victoria, Australia
🇺🇸Virginia Cancer Specialists, PC, Fairfax, Virginia, United States
🇺🇸Texas Oncology, P.A. - Baylor Charles A. Sammons Cancer Center, Dallas, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath